Algorithm for diagnosis and treatment of small-cell lung cancer (SCLC)
- Authors: Gordeeva O.O.1
-
Affiliations:
- Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine Of Federal Medical Biological Agency
- Issue: Vol 31, No 7 (2024)
- Pages: 98-102
- Section: Алгоритмы
- URL: https://journals.eco-vector.com/2073-4034/article/view/646386
- DOI: https://doi.org/10.18565/pharmateca.2024.7.98-102
- ID: 646386
Cite item
Open Access
Access granted
Full Text
About the authors
Olga O. Gordeeva
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine Of Federal Medical Biological Agency
Author for correspondence.
Email: gordeeva.o@rcpcm.org
Cand. Sci. (Med.), Medical Oncologist, Chemotherapist
Russian Federation, MoscowReferences
- van Meerbeeck J.P., Fennell D.A., De Ruysscher D.K. Small-cell lung cancer. Lancet. 2011 Nov 12;378(9804):1741–55. doi: 10.1016/S0140-6736(11)60165-7.
- Gozzard P., Woodhall M., Chapman C., et al. Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study. Neurology. 2015 Jul 21;85(3):235–39. doi: 10.1212/WNL.0000000000001721.
- Kreisman H., Wolkove N., Quoix E. Small cell lung cancer presenting as a solitary pulmonary nodule. Chest. 1992;101(1):225–31.
- Silva M., Galeone C., Sverzellati N., et al. Screening with low-dose computed tomography does not improve survival of small cell lung cancer. J Thorac Oncol. 2016;11(2):187–93.
- Чубенко В.А., Бычков М.Б., Деньгина Н.В. и др. Практические рекомендации по лекарственному лечению мелкоклеточного рака легкого. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли. 2023;13(3s2):66–71. [Chubenko V.A., Bychkov M.B., Dengina N.V., et al. Practical recommendations for drug treatment of small cell lung cancer. Practical recommendations RUSSCO, part 1. Malignant tumors. 2023;13(3s2):66–71. (In Russ.)].
- Wakeam E., Acuna S.A., Leighl N.B., et al. Surgery versus chemotherapy and radiotherapy for early and locally advanced small cell lung cancer: a propensity-matched analysis of survival. Lung Cancer. 2017;109:78–88.
- Yang CF, Chan DY, Speicher PJ, et al. Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer. J Clin Oncol. 2016;34(10):1057–64.
- De Ruysscher D., Pijls-Johannesma M., Vansteenkiste J., et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol. 2006;17:543–52.
- Cheng Y., Spigel D.R., Cho B.C., et al.; ADRIATIC Investigators. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. N Engl J Med. 2024 Sep 13. doi: 10.1056/NEJMoa2404873. Epub ahead of print. PMID: 39268857.
- Horn L., Mansfield A.S., Szczesna A., et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229.
- Paz-Ares L., Dvorkin M., Chen Y., et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–39.
- Slotman B.J., van Tinteren H., Praag J.O., et al. Use of thoracic radiotherapy for extensive stage small cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36–42.
Supplementary files
